

BATLIBOI & PUROHIT
Chartered Accountants

REVIEW REPORT TO THE BOARD OF DIRECTORS OF
CHEMO PHARMA LABORATORIES LIMITED

1. We have reviewed the accompanying statement of audited financial results of **Chemo Pharma Laboratories Ltd., ("the Company")** for the quarter ended 30th June, 2015 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, [notified pursuant to the Company's (Accounting Standards) Rules, 2006 as (amended)] and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai
Dated : 23/7/2015



For **BATLIBOI & PUROHIT**
Chartered Accountants
Firm Reg. No. 101048W

Paresh Chokshi
Paresh Chokshi
Partner
Membership No.33597

CHEMO PHARMA LABORATORIES LIMITED

• EMPIRE HOUSE, 3RD FLOOR, 214, DR. D.N. ROAD, FORT, MUMBAI - 400 001
 • TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294
 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 www.thechemopharmalaboratoriesltd.com
 EMAIL: chemopharmalab@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2015

(Rs in '000)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30th June 2015	31st March 2015	30th June 2014	31st March, 2015
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	(a) Net Sales/ Income from Operations (Net of excise duty)	-	-	-	-
	(b) Other Operating Income	-	-	-	-
	Total Income from operations (net)	785	2,480	1,102	5,044
2	Expenses	785	2,480	1,102	5,044
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expenses	-	-	-	-
	(e) Depreciation and amortisation expense	111	113	48	305
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	14	34	42	242
	i) Professional Charges	9	341	-	448
	ii) Share Registry Expenses	19	21	18	85
	iii) Annual Listing Fees	225	-	-	125
	Total Expenses	378	482	116	1,205
3	Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)	407	1,998	986	3,839
4	Other Income	-	-	-	-
5	Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)	407	1,998	986	3,839
6	Finance Costs	-	-	-	-
7	Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)	407	1,998	986	3,839
8	Exceptional items	-	-	-	-
9	Net Profit/(Loss) from ordinary activities before tax (7+8)	407	1,998	986	3,839
10	Tax expenses	-	1,040	-	1,040
11	Net Profit/(Loss) from ordinary activities after tax (9+10)	407	958	986	2,799
12	Extra ordinary items (net of tax expenses Rs.)	-	-	-	-
13	Net Profit/ (Loss) for the period (11+12)	407	958	986	2,799
14	Share of Profit/ (Loss) of associate*	-	-	-	-
15	Minority interest *	-	-	-	-
16	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	407	958	986	2,799
17	Paid-up equity share Capital (face value of Rs. 10/- each)	15,000	15,000	15,000	15,000
18	Reserves excluding revaluation reserve as per balance sheet of previous accounting year	36,217	36,217	33,506	36,217
19	i) Earning per share (before extraordinary items) of Rs. 10/- each) (not annualised) :				
	(a) Basic	0.27	0.64	0.66	1.87
	(b) Diluted				
19	ii) Earning per share (after extraordinary items) of Rs. 10/- each) (not annualised) :				
	(a) Basic	0.27	0.64	0.66	1.87
	(b) Diluted				



CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294

CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

www.thechemopharmalaboratoriesltd.com

EMAIL: chemopharmalab@gmail.com

A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares				
	- Percentage of shareholding	1,081,719	1,081,719	1,081,719	1,081,719
19	Promoters and Promoter Group shareholding**	72.12	72.12	72.12	72.12
	a) Pledged/Encumbered				
	- Number of shares				
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of promoter and promoter group)	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares				
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	418,281	418,281	418,281	418,281
	- Percentage of shares (as a % of the total share capital of company)	100	100	100	100
		27.88	27.88	27.88	27.88

Particulars		Quarter Ended 30.06.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

Note :

- The above Unaudited Financial Results for the quarter ended 30.06.2015 have been reviewed by the Audit Committee in their Meeting held on 23.07.2015 and approved by the Board of Directors of its Meeting held on 23.07.2015. The Limited Review Report of Auditors M/s Batliboi & Purohit was also taken on record by the Board in its Meeting.
- Separate segment reporting is not applicable to the company.

Place : Mumbai
Date : 23rd July 2015



For Chemo - Pharma Laboratories Limited

Asst. Director

Director